EC-Biotech: a true hidden gem, if not the jewel in the crown (of thorns)---"treatment no less favourable"

As I recall Joost's excavation of the gems in EC-Biotech may not have included the panel's analysis of Art. III:4 of the GATT, National Treatment.  As I understand it, fleshing out the meaning of what the AB said about "treatment no less favorable' in EC-Asbestos (para 100), as well as DR-Cigarettes,  the panel concluded that only differences of treatment between "like" products that are based on national origin as opposed to legitimate, neutral regulatory concerns constitute "treatment no less favorable" within the meaning of III:4.  Aims-and-effects redux?  Para. 7.2505.